Anthony Coles - Regeneron Pharmaceuticals Independent Director

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;padding-top: 25px;;'>RP</div>
REGN -- USA Stock  

Report: 5th of August 2020  

  Director
Dr. N. Anthony Coles, M.D., is Independent Director of the Company. has served as Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, since October 2014. Prior to this, from October 2013, Dr. Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer, and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck Co., Inc., BristolMyers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporationrationration of America Holdings, Campus Crest Communities, Inc., and CRISPR Therapeutics AG. Dr. Coles was a director of McKesson Corporationrationration since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors.
Age: 57  Director Since 2017      
914 847-7000  www.regeneron.com

Regeneron Pharmaceuticals Management Efficiency

Regeneron Pharmaceuticals has return on total asset (ROA) of 10.77 % which means that it generated profit of $10.77 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 21.13 %, meaning that it created $21.13 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Regeneron Pharmaceuticals Return on Invested Capital is quite stable at the moment as compared to the past year. The company's current value of Return on Invested Capital is estimated at about 0.25. Return on Sales is projected to rise to 0.27 this year, although the value of Return on Investment will most likely fall to 19.90. Regeneron Pharmaceuticals Total Assets Per Share are quite stable at the moment as compared to the past year. The company's current value of Total Assets Per Share is estimated at about 144.86. Asset Turnover is projected to rise to 0.61 this year, although the value of Net Current Assets as percentage of Total Assets will most likely fall to 36.01. Total Liabilities is projected to rise to about 4 B this year. Current Liabilities is projected to rise to about 2.3 B this year
The company currently holds 715.2 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Regeneron Pharmaceuticals has a current ratio of 4.13, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Fred WeissAllergan Plc
2013
J MoreauDr Reddys Laboratories
2007
Geoffrey ParkerPerrigo Company Plc
2016
Peter McDonnellAllergan Plc
2015
Kalpana MorpariaDr Reddys Laboratories
2007
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
William YoungVertex Pharmaceuticals Incorpor
2014
Adriana KaraboutisPerrigo Company Plc
2017
Linda RhodesZoetis Inc
2017
Ravi BhoothalingamDr Reddys Laboratories
2000
Michael GallagherAllergan Plc
2015
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
James KiltsPfizer Inc
2007
Scott GottliebPfizer Inc
2019
Jeffrey KindlerPerrigo Company Plc
2017
Rolf ClassonPerrigo Company Plc
2017
Herman MorrisPerrigo Company Plc
1999
Thomas FreymanAllergan Plc
2018
Frances FergussonPfizer Inc
2009
Christopher BodineAllergan Plc
2013
Don CornwellPfizer Inc
1997

Company Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on BATS Exchange. It employs 8030 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 8,030 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module

Currently Active Assets on Macroaxis

S   
Sold over 300 shares of
six days ago
Traded for 8.62
GM   
Sold over 100 shares of
six days ago
Traded for 25.24
XOM   
Sold over 60 shares of
six days ago
Traded for 44.08
OTPBF   
Sold over 100 shares of
six days ago
Traded for 28.82
MSFT   
Sold few shares of
six days ago
Traded for 206.26
Additionally, take a look at Your Equity Center. Please also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page